Capital Impact Advisors, LLC Beam Therapeutics Inc. Transaction History

Capital Impact Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$17.69 - $30.76 $145,571 - $253,124	8,229 New	8,229 $223,000
Q1 2023 May 23, 2023	BUY	$30.15 - $48.79 $13,416 - $21,711	445 Added 3.66%	12,600 $385,000
Q4 2022 Feb 14, 2023	BUY	$36.73 - $51.6 $16,822 - $23,632	458 Added 3.92%	12,155 $475,000
Q3 2022 Nov 21, 2022	BUY	$39.79 - $70.31 $110,059 - $194,477	2,766 Added 30.97%	11,697 $554,000
Q2 2022 Aug 15, 2022	BUY	$29.86 - $62.36 $51,717 - $108,007	1,732 Added 24.06%	8,931 $346,000
Q1 2022 May 16, 2022	SELL	$53.73 - $82.16 $14,668 - $22,429	-273 Reduced 3.65%	7,199 $413,000
Q4 2021 Feb 14, 2022	BUY	$68.02 - $99.06 $508,245 - $740,176	7,472 New	7,472 $595,000
Q1 2021 May 18, 2021	SELL	$71.28 - $120.75 $1.78 Million - $3.02 Million	-25,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$22.24 - $95.63 $556,000 - $2.39 Million	25,000 New	25,000 $2.04 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.